| Echocardiographic characteristics |
BiPAP group (19) |
Standard therapy -11 |
Control group (15) |
| LVFS% |
45.64 ± 5.48 |
45.87 ± 6.87 |
60.37 ± 6.30
p-0.439 |
| EF % |
45.64 ± 5.48 |
45.87 ± 6.87 |
60.37 ± 6.30
p-0.439 |
| Septum, mm |
13.75 ± 2.1 |
11.82 ± 2.2 |
12.68 ± 1.53
p-0.658 |
| BW,mm |
13.29 ± 1.8 |
12.76 ± 1.9 |
12.66 ± 1.63
p-0.721 |
| Blood pressure characteristics |
| Diurnal Systolic Blood Pressure, mmHg |
134.66 ± 8.17 |
142.3 ± 9.48 |
136.28 ± 13.81
p-0.092 |
| Diurnal Diastolic Blood Pressure, mmHg |
80.01 ± 9.31 |
81.3 ± 9.82 |
82.8 ± 8.89
p-0.794 |
| Nocturnal Systolic Blood Pressure, mmHg |
126.05 ± 9.63 |
109.2 ± 8.12 |
121.85 ±10.57
p-0.091 |
| Nocturnal Diastolic Blood Pressure, mmHg |
78.8 ± 9.41 |
67.3 ± 9.65 |
73.02 ± 7.33
p-0.459 |
| Cardiomyopathy |
| Ischaemic/Non-ishaemic |
8/19 (42%) |
6/11(55%) |
1/15(6%) |
| Diabetics |
5/19(26%) |
4/11(36%) |
2/15(13%) |
| Imapired glucose tolerance |
5/19(26%) |
0 |
8/15(53%) |
| Normal glucose metabolism |
9/19(47%) |
7/11(64%) |
5/15(33%) |
| Treatment |
| ACEI |
18/19 (95%) |
9/11(82%) |
13/15(87%) |
| B-Blockers |
12/19 (63%) |
7/11(63%) |
10/15(67%) |
| Diuretics |
17/19(89%) |
8/11(72%) |
9/15(60%) |
